Is Autoimmune Hepatitis Contagious?

Autoimmune hepatitis is not contagious. You cannot catch it from another person, pass it to a partner, or transmit it to your children through casual contact, bodily fluids, or any other route. Unlike viral hepatitis (hepatitis A, B, or C), which is caused by infectious viruses that spread between people, autoimmune hepatitis is an inflammatory liver disease driven by the body’s own immune system mistakenly attacking liver tissue.¹ The confusion between the two is understandable given the shared word “hepatitis,” and it creates real problems for people living with the condition.

Why the Name Causes Confusion

“Hepatitis” simply means inflammation of the liver. It is not a single disease but a category, and that category includes infections (hepatitis A through E), alcohol-related damage, fatty liver disease, and autoimmune causes. When most people hear “hepatitis,” they think of viral infections, especially hepatitis B and C, both of which can spread through blood or sexual contact. That association is so deeply ingrained that someone diagnosed with autoimmune hepatitis often fields worried questions from friends and family about whether they can spread it.

The naming history does not help. In the 1950s and 1960s, the condition was initially called “lupoid hepatitis” because early patients showed certain immune markers resembling those seen in lupus.² Before that, chronic liver inflammation of this kind was sometimes attributed to a persistent virus that researchers had not yet identified. Once scientists recognized that the immune system itself was the culprit, the terminology shifted, but “hepatitis” stuck in the name. That single word continues to carry infectious connotations for anyone unfamiliar with the distinction.

What Actually Causes the Liver Damage

In autoimmune hepatitis, your immune system loses tolerance to your own liver cells. Normally, immune cells are trained not to attack the body’s own tissues. In people with this condition, that training breaks down. A specific class of immune cells recognizes liver proteins as foreign and mounts a sustained attack, creating chronic inflammation that, left untreated, leads to scarring and eventually cirrhosis.³

Liver biopsies from people with autoimmune hepatitis show a dense infiltration of immune cells around and within the liver tissue, including T cells, B cells, plasma cells, and macrophages. High numbers of certain inflammatory T cells correlate with the severity of liver damage, pointing to a combined cellular immune attack against the organ.³ Nothing about this process involves an external pathogen that could be passed from one person to another. The problem is entirely internal: the immune system misidentifying its own tissue as an enemy.

Genetic Risk Factors

If autoimmune hepatitis is not infectious, why do some families see more than one member develop it? The answer lies in genetics, not transmission. Certain inherited immune-system gene variants make a person more susceptible. In white populations, variants encoding specific immune markers called DR3 and DR4 on immune cells are strongly linked to the disease. One study found that a particular gene sequence was present in about 94% of patients compared to 64% of matched healthy controls.⁴ In Japanese patients, a different variant of the DR4 gene appears to be the primary susceptibility factor, with DR4 found in roughly 89% of patients.⁵

These gene variants are inherited, not transmitted like an infection. Having them raises your risk but does not guarantee you will develop the disease. Most people who carry these variants never get autoimmune hepatitis. It takes additional triggers, many of which remain poorly understood, to push the immune system into actually attacking the liver. Researchers believe that environmental exposures, hormonal factors, and possibly prior infections may act as those triggers in genetically predisposed individuals, but the disease itself has no infectious agent to spread.

Familial Clustering Is About Shared Genes, Not Contagion

A large Danish registry study tracked families of people diagnosed with autoimmune hepatitis and found that first-degree relatives had about five times the expected rate of developing the condition themselves, though the absolute risk remained very low at roughly 0.1% over ten years.⁶ Among identical twins, who share virtually all their DNA, the concordance rate was around 9%, while fraternal twins showed no concordance at all. That pattern, where identical twins are affected much more often than fraternal twins, is a hallmark of genetic influence.

A Swedish population study also found a raised risk among siblings, with siblings being about four times more likely than the general population to be diagnosed.⁷ Interestingly, that same study detected elevated spousal risks as well, which at first glance might seem to hint at environmental sharing or even transmission. Researchers interpret spousal clustering cautiously, noting it likely reflects shared environment (diet, exposures, socioeconomic factors) or assortative mating rather than any form of contagion. It is worth noting that no mechanism for person-to-person spread of autoimmune hepatitis has ever been identified or even seriously proposed.

Triggers That Are Not the Same as Causes

Some people develop autoimmune hepatitis shortly after a viral infection or after taking certain medications, which can understandably make it look like the virus or drug “caused” a contagious disease. What actually happens is that the infection or drug acts as a trigger, disturbing immune tolerance in someone who was already genetically prone. The virus itself is not what damages the liver long-term; the immune system’s misdirected response is.

Drug-induced autoimmune hepatitis is a recognized variant. Medications like nitrofurantoin (a common urinary tract antibiotic) and minocycline (used for acne) are among the most frequently implicated. Patients with this form have similar autoantibody profiles and liver biopsy findings as those with the spontaneous form of the disease.⁸ The key clinical difference is the prognosis: once the offending drug is stopped, most patients with drug-induced autoimmune hepatitis do not relapse after immunosuppressive treatment is withdrawn, whereas patients with the spontaneous form relapse roughly two-thirds of the time.⁸ In neither case is the condition something that can be passed to anyone else.

Drug-induced cases can present more acutely, sometimes with fever, skin rash, and swollen lymph nodes, which may further alarm patients and their families into wondering about infection. Up to about 30% of drug-induced cases have these allergic-type features.⁹ But those symptoms reflect the immune system’s overreaction to the medication, not the presence of a transmissible pathogen.

How Autoimmune Hepatitis Is Diagnosed

Part of what separates autoimmune hepatitis from viral hepatitis in a clinical setting is the diagnostic workup. Doctors look for characteristic autoantibodies circulating in the blood. Type 1 autoimmune hepatitis, the more common form, is marked by antinuclear antibodies and smooth muscle antibodies. Type 2, which tends to appear in younger patients, is defined by a different set of antibodies directed against liver and kidney tissue.¹⁰ Elevated immunoglobulin G levels and certain biopsy patterns round out the diagnostic picture.¹¹

Crucially, the diagnosis also involves ruling out viral hepatitis. Patients are tested for hepatitis A, B, and C viruses. If those tests come back negative and the autoantibody and immunoglobulin profile fits, the picture shifts toward an autoimmune cause. This is one of the clearest ways in which the two categories of hepatitis are formally distinguished: one shows viral markers, the other shows autoimmune markers. You will never test positive for a hepatitis virus because of autoimmune hepatitis.

Treatment and What It Tells You About the Disease

The standard treatment for autoimmune hepatitis is immunosuppressive medication, typically a corticosteroid (prednisone or prednisolone) combined with azathioprine. Roughly 75% to 90% of patients respond well to this approach.¹² In one long-term study, about 83% of patients remained in remission on azathioprine alone for a median of roughly five and a half years.¹³

The fact that the disease responds to immunosuppression rather than antiviral drugs is itself telling. Viral hepatitis B and C are treated with antiviral medications that target the virus directly. Autoimmune hepatitis is treated by calming the immune system down. The therapeutic logic is completely different because the underlying problem is completely different. Combined steroid and azathioprine treatment has been shown to substantially reduce the risk of death or need for transplant compared to no immunosuppressive therapy.¹⁴

Stigma and the Costs of Misunderstanding

The confusion between autoimmune and viral hepatitis is not just an academic problem. It carries real social consequences. Research on perceived stigma shows that people with autoimmune hepatitis report experiencing prejudice and incorrect assumptions about their diagnosis, similar to the stigma historically associated with viral hepatitis, which itself was often wrongly tied to drug use, risky sexual behavior, or unsanitary living conditions.¹⁵

People with autoimmune hepatitis sometimes report that friends, coworkers, or even medical staff unfamiliar with the disease treat them as though they are infectious. Some feel pressure to explain repeatedly that their condition is not contagious and did not result from lifestyle choices. This perceived stigma has measurable effects on mental health and disease outcomes, adding an unnecessary psychological burden on top of a chronic illness that already demands lifelong monitoring and, usually, lifelong medication.

Pregnancy and Autoimmune Hepatitis

Women with autoimmune hepatitis who become pregnant sometimes worry about transmitting the condition to their baby. Because the disease is not caused by an infectious agent, there is no vertical transmission the way hepatitis B can pass from mother to child during birth. The concern during pregnancy is managing the disease, not preventing contagion. In a large international cohort study, about 88% of pregnancies in women with autoimmune hepatitis resulted in live births, though complications like preterm delivery occurred in about a quarter of cases.¹⁶

The challenges during pregnancy involve balancing immunosuppressive treatment with fetal safety and managing the risk that the disease may flare postpartum, when the immune system rebounds after the natural immune suppression of pregnancy eases. Autoimmune hepatitis can be more unpredictable in the postpartum period, and close monitoring is essential. But the baby does not “catch” the disease. A child born to a mother with autoimmune hepatitis may carry a modestly elevated genetic risk, as the familial studies suggest, but that risk is small and genetic in nature.

The Gut-Liver Axis and Emerging Research

One active area of research involves the relationship between the gut and the liver in autoimmune hepatitis. Studies have found that patients often have increased intestinal permeability, sometimes called “leaky gut,” along with changes in the composition of their gut bacteria. These microbial shifts correlate with disease severity.¹⁷ The idea is that when the intestinal barrier becomes more permeable, bacterial products can reach the liver through the portal vein and provoke or sustain immune activation there.¹⁸

This line of research could one day lead to new therapeutic strategies, perhaps involving probiotics, dietary modifications, or treatments aimed at restoring a healthy gut barrier. But it also adds another layer of nuance to why autoimmune hepatitis develops. It is not one single cause but an interplay of genetic susceptibility, immune dysregulation, and environmental factors like gut health. None of those factors involve an infectious agent that someone else could give you.

Rising Incidence Around the World

Autoimmune hepatitis appears to be getting more common globally. A systematic review covering data from 1970 through 2022 found a statistically significant upward trend in both incidence and prevalence over time.¹⁹ Whether this reflects genuinely more cases or better recognition and diagnostic tools is debated, and the truth is probably a mix of both. What the rising numbers do not reflect is any kind of spreading infection. Countries with increasing diagnosis rates are not experiencing outbreaks; they are identifying a condition that was previously under-recognized, particularly in populations outside of Northern Europe and North America where the disease was historically studied most.

The female predominance is also notable. Women are affected roughly three to four times more often than men, a pattern consistent with many autoimmune diseases (rheumatoid arthritis, lupus, multiple sclerosis) and further evidence that hormonal and genetic factors drive risk, not an infectious exposure that would affect both sexes equally.

Overlap With Other Autoimmune Liver Diseases

Some patients have features of autoimmune hepatitis alongside another autoimmune liver condition, most commonly primary biliary cholangitis or primary sclerosing cholangitis. These “overlap syndromes” can complicate diagnosis and treatment. Neither primary biliary cholangitis nor primary sclerosing cholangitis is contagious either; both involve immune-mediated damage to bile ducts rather than to liver cells directly. The existence of overlap reinforces the autoimmune nature of all these conditions. They cluster together in the same patients because they share underlying immune dysregulation, not because one infection causes multiple diseases.

Families of people with autoimmune hepatitis also show modestly increased rates of other autoimmune diseases beyond just liver conditions. The Swedish familial study found associations between autoimmune hepatitis and primary biliary cholangitis within families.⁷ This kind of clustering across different autoimmune diseases in the same family tree is one of the strongest pieces of evidence that the genetic underpinning is about immune regulation in general, not about any particular pathogen.